Amarin Corp Plc (AMRN)

[couldbebetter]

Indeed, Once China approves the CVD indication for Vascepa
that will be a massive opportunity for Edding. For any potential
BP acquirer the question may be if there are strategies a BP could
employ to help Edding optimize (and hold) that market. The exclusivity
protection (as is for Europe out to 2039) does not exist in China. Edding
not only needs to make Vascepa a winner but must protect their market
once it is established. That may be a critical factor for any potential BP
acquirer of AMRN as revenues in China could be of blockbuster proportions.
Protecting against competition will be critical.